8-K: Fractyl Health Announces Q4 and Full Year 2024 Results, Highlights Progress in Obesity and Type 2 Diabetes Therapies

Fractyl Health reports financial results and business updates, emphasizing strong demand for its REMAIN-1 study and plans for Rejuva's clinical trial application.

Summary

• Fractyl Health announced its fourth quarter and full year 2024 financial results and provided a corporate update on March 3, 2025.
• The company is focused on developing therapies for obesity and Type 2 Diabetes (T2D).
• A key focus is on sustaining weight loss after GLP-1 therapy.
• The REMAIN-1 pivotal study is evaluating weight maintenance after discontinuing GLP-1 drugs and has seen strong patient and physician demand with over 189 patients enrolled across 13 clinical sites in six months.
• Midpoint data analysis for REMAIN-1 is anticipated in Q2 2025, with full study enrollment expected in summer 2025.
• The company plans to submit the first Clinical Trial Application (CTA) module for RJVA-001 in T2D to regulators in H1 2025, with preliminary data expected in 2026 if the CTA is authorized.
• In January, Fractyl Health decided to focus Revita exclusively on weight maintenance and paused investment in Revita programs for T2D.
• Revenue for both the quarters ended December 31, 2024 and 2023 was generated from the German Real-World Commercial Registry.
• Research and development expenses were $20.3 million for the quarter ended December 31, 2024, compared to $10.1 million for the same period in 2023.
• Selling, general, and administrative expenses were $4.9 million for the quarter ended December 31, 2024, compared to $2.8 million for the same period in 2023.
• Net loss was $25.0 million for the quarter ended December 31, 2024, compared to a net loss of $19.2 million for the same period in 2023.
• As of December 31, 2024, Fractyl had approximately $67.5 million in cash and cash equivalents.
• The company believes its existing cash will fund operations through key clinical milestones into 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is experiencing losses, it has a clear strategic focus, promising clinical programs, and sufficient cash to fund operations into 2026. The strong demand for the REMAIN-1 study is also a positive indicator.

Positives

• Strong patient and physician demand for the REMAIN-1 study indicates a significant unmet need for weight maintenance solutions after GLP-1 discontinuation.
• Focusing Revita on weight maintenance allows for disciplined capital allocation and strengthens the company's competitive positioning.
• The company's cash position of $67.5 million is expected to fund operations through key clinical milestones into 2026.
• Advancement of the Rejuva gene therapy platform towards first-in-human studies represents a potential future growth driver.
• The company anticipates submitting the first CTA module for RJVA-001 in T2D to regulators in H1 2025.

Negatives

• The company experienced a net loss of $25.0 million for the quarter ended December 31, 2024, an increase from the $19.2 million loss in the same period of 2023.
• Increased research and development and selling, general, and administrative expenses contributed to the higher net loss.
• The company paused investment in its Revita programs for T2D, which consisted of the REVITALIZE-1 study, and the Germany Real-World Registry study.

Risks

• Clinical trial outcomes are uncertain, and the REMAIN-1 study may not yield positive results.
• Regulatory approval for RJVA-001 is not guaranteed, and the timeline for approval could be lengthy.
• The company's reliance on third parties for manufacturing and clinical studies poses a risk to its operations.
• The company has a limited operating history and has incurred significant net losses, raising concerns about its long-term financial sustainability.
• The company's ability to continue as a going concern is dependent on securing additional financing.

Future Outlook

The company believes its existing cash and cash equivalents will be sufficient to fund operations through key anticipated company clinical milestones into 2026. They anticipate a midpoint data analysis of REMAIN-1 in the second quarter of 2025 and full study enrollment in summer 2025. The Company plans to submit the first Clinical Trial Application (CTA) module for RJVA-001 in type 2 diabetes to regulators in H1 2025, and if CTA is authorized, expects to report preliminary data in 2026.

Management Comments

• The future of obesity care isn't just about losing weight it's about keeping it off, said Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health.
• At Fractyl, we are pioneering a new treatment paradigm that moves beyond short-term fixes to deliver lasting metabolic solutions.
• Our goal is to provide patients and physicians with something they don't have today: a science-driven approach to long-term weight maintenance and metabolic health.
• With multiple key anticipated clinical milestones ahead in our REVEAL-1 and REMAIN-1 studies, and Rejuva advancing toward first-in-human studies, we believe 2025 will be a pivotal year one that marks a major transformation in obesity and T2D treatment.
• We remain laser-focused on our efforts to deliver the innovations that will change the trajectory of these diseases for millions worldwide.

Industry Context

Fractyl Health is operating in the rapidly growing market for obesity and T2D treatments, focusing on addressing the challenge of maintaining weight loss after GLP-1 therapy, a significant unmet need. The company's focus on durable, disease-modifying therapies aligns with the broader industry trend towards addressing the root causes of metabolic diseases.

Comparison to Industry Standards

• Fractyl's REMAIN-1 study is focused on weight maintenance after GLP-1 discontinuation, a niche area compared to companies like Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Mounjaro, Zepbound) that focus on initial weight loss.
• The Rejuva gene therapy platform is a novel approach, differentiating Fractyl from companies pursuing traditional pharmaceutical or device-based therapies.
• The company's cash runway into 2026 is a positive sign, but its relatively small size and limited revenue compared to industry giants present challenges.

Stakeholder Impact

• Shareholders: The strategic focus and clinical progress could positively impact shareholder value, but ongoing losses and the need for potential future financing pose risks.
• Employees: The strategic reprioritization and workforce reduction may impact employee morale and job security.
• Patients: Successful development of Revita and Rejuva could provide new treatment options for obesity and T2D patients.
• Physicians: The REMAIN-1 study results could provide valuable data on weight maintenance strategies after GLP-1 discontinuation.

Next Steps

• The company anticipates a midpoint data analysis of REMAIN-1 in Q2 2025.
• Full study enrollment in REMAIN-1 is expected in summer 2025.
• The company plans to submit the first CTA module for RJVA-001 in T2D to regulators in H1 2025.
• Preliminary data for RJVA-001 is expected in 2026 if the CTA is authorized.
• Additional data from the REVEAL-1 cohort is expected to be presented in the first quarter of 2025.

Key Dates